A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

Protocol No

NURIX-NX-5948-301

Staff Member

Nirav Shah

Phase

I

Summary

This project is being done to evaluate whether NX-5948, which will be called the “study drug” throughout the ICF, is safe and tolerated, and identify the highest safe dose that can be given. Another main purpose of this study is to evaluate whether NX-5948 has an effect on B-cell lymphomas and leukemias.

Objective

A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL